Thank you for donating!

You can donate using the following services.

Posts filed in: "IntraBio"

  1. 20.02.20

    Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

    Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has completed patient enrollment in its Phase I/II trial to evaluate the safety, tolerability, and efficacy of Trappsol® Cyclo™ administered intravenously to Niemann-Pick Disease Type C1 (NPC1) patients...

    Read more
  2. 12.02.20

    Last Patient Last Visit in Cyclo Therapeutics’ Phase I Trial in Niemann-Pick Type C

    GAINESVILLE, FL – (Businesswire) – February 11, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the last patient has undergone the final assessment in its Phase I trial to evaluate the safety and tolerability of Trappsol® Cyclo™ administered intravenously to NPC patients.

    Read more
  3. 05.02.20

    Cyclo Therapeutics, Inc. Poster Presentation of Clinical Trial Data on Niemann-Pick Type C Disease at the 16th Annual WORLDSymposium Now Available

    Data show that Trappsol® Cyclo™, the Company’s proprietary hydroxypropyl beta cyclodextrin drug, reduces levels of trapped cholesterol in liver tissue of Niemann-Pick Disease Type C Patients...

    Read more
  4. 30.01.20

    Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency

    Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency...

    Read more
  5. 17.01.20

    IntraBio Completes NPC Clinical Trial Enrollment

    OXFORD, UK / ACCESSWIRE / January 17, 2020, / IntraBio Inc, a late-stage biopharmaceutical company, is pleased to share that it has completed enrollment for its IB1001-201 Clinical Trial...

    Read more